AstraZeneca Pharma India Share Price

AstraZeneca Share Recommendations

AstraZeneca Financials

AstraZeneca Peer Comparison

AstraZeneca Shareholding Pattern

AstraZeneca MF Ownership

• Nippon India Small Cap Direct-G

  Equity: Small Cap

  4.0

  • 571.27

    Amount Invested (in Cr.)

  • 0.98%

    % of AUM

  • 0.00

    % Change (MoM basis)

• Bandhan Innovation Direct-G

  Equity: Thematic

  • 58.01

    Amount Invested (in Cr.)

  • 4.05%

    % of AUM

  • 2.72

    % Change (MoM basis)

• Nippon India Pharma Direct-G

  Equity: Sectoral-Pharma

  3.0

  • 55.63

    Amount Invested (in Cr.)

  • 0.67%

    % of AUM

  • 0.00

    % Change (MoM basis)

AstraZeneca Corporate Actions

About AstraZeneca

AstraZeneca Pharma India Ltd., incorporated in the year 1979, is a Mid Cap company (having a market cap of Rs 25,446.38 Crore) operating in Pharmaceuticals sector. AstraZeneca Pharma India Ltd. key Products/Revenue Segments include Pharmaceuticals and Sale of services for the year ending 31-Mar-2024.For the quarter ended 31-03-2025, the company has reported a Standalone Total Income of Rs 496.63 Crore, up 10.79 % from last quarter Total Income of Rs 448.27 Crore and up 26.74 % from last year same quarter Total Income of Rs 391.86 Crore. Company has reported net profit after tax of Rs 58.25 Crore in latest quarter.The company’s top management includes Mr.Narayan K Seshadri, Ms.Bhavana Agrawal, Mr.Sanjeev Kumar Panchal, Ms.Hooi Bien Chuah, Ms.Sylvia Lorena Varela Ramon, Ms.Revathy Ashok, Ms.Shilpa Divekar Nirula, Ms.Bhavana Agrawal, Ms.Manasa Rama. Company has Price Waterhouse & Co Chartered Accountants LLP as its auditors. As on 31-03-2025, the company has a total of 2.50 Crore shares outstanding.AstraZeneca Share Price Today is Rs. 10509.50. On previous day, the AstraZeneca Share Price (NSE) closed at Rs. 10195.0, featuring among the most traded securities on the National Stock Exchange.

Shareholdings:
As of 31st Mar, 2025, the promoter held 75.0% of the stake in AstraZeneca shares, out of which 0.0% was pledged. On the same date, foreign institutional investors' (FII) holdings of AstraZeneca stocks was 2.89% as compared to 2.92% in Dec 2024 with decrease of 0.03%. The domestic institutional investors (DII) holdings on 31st Mar, 2025 was 4.64% as compared to 5.2% in Dec 2024 with decrease of 0.56%. Out of the total DII holdings in AstraZeneca shares 4.45% was held by mutual funds. The rest including public held is 17.47%. AstraZeneca stock price is reflected on both the exchanges - BSE and NSE.

Dividend, Bonus & Split Information:
AstraZeneca Dividend: Ever since 1979, AstraZeneca dividends has been paid out around 25 times. As on 13 Jun, 2025, 03:58 PM IST, The overall dividend yield for AstraZeneca stands at 0.0%. The last dividend paid was on July 5, 2024 (Rs. 24.0). The Earnings Per Share (EPS) for quarter ending 31st Mar 2025 is Rs. 46.3.

AstraZeneca Bonus: The most recent bonus issue had been in year November 13, 1995 around 29 years ago at 1 : 1 ratio. The first bonus issue was announced in Oct 1995.

Stock Forecast:
After showing 496.63 Cr. of sales and 10.79% of quarterly net profit, there have been multiple ups and downs in the AstraZeneca stock prices in the past few weeks. For example, AstraZeneca stock price on 6th of June 2025 was around Rs. 7972.0. AstraZeneca share price now stands at an average of Rs. 10509.50. Judging by last week's performance, stock is in up trend.

AstraZeneca has a median target price of Rs. 0.0 in 12 months by 0 analysts. They have provided a high estimate of Rs. 0.0 and low estimate of Rs. 0.0 for AstraZeneca share.

Historical Prices and Performance:
AstraZeneca, incorporated in 1979 is a Mid Cap company (with a market cap of Rs. 25446.38) operating in Pharmaceuticals sector.
The Return of Equity (ROE) in last five financial years given by AstraZeneca stock was 15.02%, 22.68%, 16.86%, 12.04% and 20.45% respectively.
The AstraZeneca share gave a 3 year return of 236.97% as compared to Nifty 50 which gave a return of 50.77%.
AstraZeneca announced 1200.0% final dividend on July 5, 2024.

Key Metrics:
PE Ratio of AstraZeneca is 213.49
Prices/Sales Ratio of AstraZeneca is 12.54
Price/Book Ratio of AstraZeneca is 32.08

Peer Insights:
Peers are businesses with comparable activities, buisness objectives and affiliation with a particular industry area. For AstraZeneca, major competitors and peers include Abbott India, GSK Pharma, Pfizer and Sanofi India. As of Dec 2024, the dividend yield of AstraZeneca stands at 0.0% while Abbott India, GSK Pharma, Pfizer and Sanofi India stand at 1.5%, 1.56%, 2.85% and 1.89% respectively. The PE ratio and PB Ratio of the company are among its competitors stand at 213.49 and 32.08 respectively.

Leadership of AstraZeneca :
Manasa Rama is Co. Secretary & Compl. Officer
Bhavana Agrawal is Chief Financial Officer
Narayan K Seshadri is Chairperson & Independent Director
Sanjeev Kumar Panchal is Executive Director
Bhavana Agrawal is Executive Director
Sylvia Lorena Varela Ramon is Non Executive Director
Hooi Bien Chuah is Non Executive Director
Shilpa Divekar Nirula is Independent Director
Revathy Ashok is Independent Director


Show More